INDUSTRY × Prostatic Neoplasms × Dermatologic × Clear all
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT07124000 2026-02-24

DP-04

AstraZeneca

Recruiting
100 enrolled
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

Phase 2 Recruiting
740 enrolled
NCT07341737 2026-01-15

SL-28 for Advanced Solid Tumours

Second Life Therapeutics

Phase 1/2 Not yet recruiting
60 enrolled
NCT06781983 2026-01-07

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Innate Pharma

Phase 1 Recruiting
145 enrolled
NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
NCT04068896 2025-05-29

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

NGM Biopharmaceuticals, Inc

Phase 1/2 Completed
89 enrolled 21 charts
NCT05179824 2025-05-06

Tempus Priority Study: A Pan-tumor Observational Study

Tempus AI

Active not recruiting
1,000 enrolled
NCT06583395 2024-11-01

QUANTUM

VitaMed Research LLC

Enrolling by invitation
3,000 enrolled
NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
130 enrolled
NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
71 enrolled
NCT03602079 2023-08-03

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

Phase 1/2 Completed
49 enrolled
NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Kineta Inc.

Phase 1/2 Unknown
314 enrolled
NCT03849469 2023-03-30

DUET-4

Xencor, Inc.

Phase 1 Completed
78 enrolled
NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
NCT03517488 2022-12-01

DUET-2

Xencor, Inc.

Phase 1 Completed
150 enrolled
NCT03896958 2020-12-04

PIONEER

SpeciCare

Unknown
1,000 enrolled
NCT02223052 2020-05-12

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Celgene

Phase 1 Completed
89 enrolled
NCT02262455 2017-02-13

Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors

Santa Maria Biotherapeutics

Phase 1 Completed
32 enrolled
NCT00753415 2015-03-17

A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)

Merck Sharp & Dohme LLC

Phase 1 Completed
37 enrolled 10 charts
NCT00538850 2014-03-05

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

INSYS Therapeutics Inc

Phase 3 Completed
130 enrolled 9 charts